Comparison of post-remission strategies in acute myeloid leukemia: Autologous hematopoietic stem cell transplantation versus consolidation chemotherapy

YEGİN Z. A., DİKYAR A., Kaynar L. A., Can F., ÖZKURT Z. N., Yagci M.

HEMATOLOGY REPORTS, cilt.12, sa.3, ss.51-54, 2020 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 12 Sayı: 3
  • Basım Tarihi: 2020
  • Doi Numarası: 10.4081/hr.2020.8380
  • Dergi Adı: HEMATOLOGY REPORTS
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, Academic Search Premier, EMBASE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.51-54
  • Anahtar Kelimeler: Acute myeloid leukemia, autologous hematopoietic stem cell transplantation, consolidation chemotherapy, leukemia relapse, prognosis, BLOOD, AML, REMISSION, OUTCOMES, THERAPY, ADULTS
  • Gazi Üniversitesi Adresli: Evet

Özet

Autologous Hematopoietic Stem Cell Transplantation (auto-HSCT) has become a therapeutic option for first-line consolidation in Acute Myeloid Leukemia (AML) patients with favorable and intermediate risk features. A total of 101 AML patients in first complete remission, who were not eligible for allogeneic HSCT, were randomized to receive intensive cytarabine-based chemotherapy or to undergo auto- HSCT. The probability of LFS was significantly better in auto-HSCT recipients compared to chemotherapy arm (43% vs 4.8%, p=0.008). At the end of 915 (30-4470) days of followup, the probability of overall survival was better in auto-HSCT group compared to chemotherapy, without statistical significance (79.2% vs 38.8%, p=0.054). Multivariate analysis revealed a significant predictive impact of cytogenetic risk status on OS (p=0.002, HR: 2.824, 95% CI: 1.445-5.521). Auto-HSCT is considered as an effective consolidation approach in favorable and intermadiate risk AML patients.